A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

2025-522582-30-00 Protocol ALN-5288-001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 6 sites · Protocol ALN-5288-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 50
Countries 2
Sites 6

Alzheimer’s Disease

Key facts

Sponsor
Alnylam Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Decision date (initial)
2026-02-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer’s Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Alnylam Pharmaceuticals Inc.

Sponsor organisation
Alnylam Pharmaceuticals Inc.
Address
300 3rd Street
City
Cambridge
Postcode
02142-1103
Country
United States

Scientific contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Alnylam Clinical Trial Information Line

Public contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Alnylam Clinical Trial Information Line

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Authorised, recruitment pending 7 3
Spain Authorised, recruitment pending 8 3
Rest of world
Canada, United Kingdom
35

Investigational sites

Netherlands

3 sites · Authorised, recruitment pending
Amsterdam UMC Stichting
Neurology, De Boelelaan 1117, 1081 HV, Amsterdam
Brain Research Center Amsterdam B.V.
Neurology, Cronenburg 2, 1081 GN, Amsterdam
Brain Research Center Den Bosch B.V.
Neurology, Statenlaan 37, 5223 LA, 's-Hertogenbosch

Spain

3 sites · Authorised, recruitment pending
Hospital Universitari General De Catalunya
Neurology, Carrer Pedro I Pons 1, 08195, Sant Cugat Del Valles
Hospital Clinic De Barcelona
Neurology, Calle Villarroel 170, 08036, Barcelona
Hospital Clinico San Carlos
Neurology, Calle Del Profesor Martin Lagos Sn, 28040, Madrid

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-02 Netherlands Acceptable
2026-02-09
2026-02-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-02-23 Netherlands Acceptable
2026-02-09
2026-02-23